Search Results - "BADROS, A"

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety by Badros, A Z, Vij, R, Martin, T, Zonder, J A, Kunkel, L, Wang, Z, Lee, S, Wong, A F, Niesvizky, R

“…This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with…”
Get full text

Second primary malignancies in multiple myeloma: an overview and IMWG consensus by Musto, P., Anderson, K.C., Attal, M., Richardson, P.G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B.G.M., San Miguel, J., Einsele, H., Chen, W.M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R.A., Moreau, P., Lahuerta, J.J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P.L., Nouel, A., Rajkumar, S.V., Reiman, A., Riva, E., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B.M., Palumbo, A.

“…Therapeutic advancements following the introduction of autologous stem cell transplantation and ‘novel’ agents have significantly improved clinical outcomes…”
Get full text

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation by Yared, J A, Hardy, N, Singh, Z, Hajj, S, Badros, A Z, Kocoglu, M, Yanovich, S, Sausville, E A, Ujjani, C, Ruehle, K, Goecke, C, Landau, M, Rapoport, A P

Get full text

Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate‐associated osteonecrosis by Scheper, Mark A., Badros, Ashraf, Chaisuparat, Risa, Cullen, Kevin J., Meiller, Timothy F.

“…Summary Osteonecrosis of the jaw secondary to bisphosphonate infusion (zoledronic acid‐ZA) is assumed to be a bone disease. This study investigated the effects…”
Get full text

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study by Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, van de Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J-J, de la Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S, Durie, B G M

“…Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this…”
Get full text

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies by Siegel, David, Martin, Thomas, Nooka, Ajay, Harvey, R Donald, Vij, Ravi, Niesvizky, Ruben, Badros, Ashraf Z, Jagannath, Sundar, McCulloch, Leanne, Rajangam, Kanya, Lonial, Sagar

“…Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent…”
Get full text

Second primary malignancies in multiple myeloma: an overview and IMWG consensus by Musto, P., Anderson, K.C., Attal, M., Richardson, P.G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B.G.M., San Miguel, J., Einsele, H., Chen, W.M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R.A., Moreau, P., Lahuerta, J.J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P.L., Nouel, A., Rajkumar, S.V., Reiman, A., Riva, E., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B.M., Palumbo, A.

Get full text

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy by Zangari, Maurizio, Anaissie, Elias, Barlogie, Bart, Badros, Ashraf, Desikan, Raman, Gopal, A. Viju, Morris, Christopher, Toor, Amir, Siegel, Eric, Fink, Louis, Tricot, Guido

“…The occurrence of deep-vein thrombosis (DVT) in patients with newly diagnosed multiple myeloma, who were randomly assigned to receive identical induction…”
Get full text

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients by Barlogie, Bart, Desikan, Raman, Eddlemon, Paul, Spencer, Trey, Zeldis, Jerome, Munshi, Nikhil, Badros, Ashrof, Zangari, Maurizio, Anaissie, Elias, Epstein, Joshua, Shaughnessy, John, Ayers, Dan, Spoon, Dan, Tricot, Guido

“…This report of a phase 2 trial of thalidomide (THAL) (200 mg/d; 200 mg increment every 2 weeks to 800 mg) for 169 patients with advanced myeloma (MM) (abnormal…”
Get full text

Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning by Badros, A.

Get full text

Clinical activity of arsenic trioxide for the treatment of multiple myeloma by MUNSHI, N. C, TRICOT, G, DESIKAN, R, BADROS, A, ZANGARI, M, TOOR, A, MORRIS, C, ANAISSIE, E, BARLOGIE, B

“…Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a…”
Get full text

P31 SINGLE‐AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM‐2 TRIAL by Nooka, A., Cohen, A., Lee, H., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E., Chaudhry, M., Hultcrantz, M., Kortüm, K.M., Richardson, P., Popat, R., Sborov, D., Hakim, S., Lewis, E., Bhushan, B., Gorsh, B., Gupta, I., Opalinska, J., Lonial, S.

Get full text

Results of autologous stem cell transplant in multiple myeloma patients with renal failure by Badros, Ashraf, Barlogie, Bart, Siegel, Eric, Roberts, Jennifer, Langmaid, Candi, Zangari, Maurizio, Desikan, Raman, Shaver, Mary Jo, Fassas, Athanasios, McConnell, Scott, Muwalla, Firas, Barri, Yousri, Anaissie, Elias, Munshi, Nikhil, Tricot, Guido

“…Data are presented on 81 multiple myeloma (MM) patients with renal failure (creatinine > 176·8 μmol/l) at the time of autologous stem cell transplantation…”
Get full text

P13: CAN PATIENT‐REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? by Popat, R, Badros, A, Kumar, S, Rodriguez‐Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E

Get full text

A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use by Jonsson, F, Ou, Y, Claret, L, Siegel, D, Jagannath, S, Vij, R, Badros, A, Aggarwal, S, Bruno, R

“…Change in tumor size estimated using longitudinal tumor growth inhibition (TGI) modeling is an early predictive biomarker of clinical outcomes for multiple…”
Get full text

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study by Greenberg, A J, Philip, S, Paner, A, Velinova, S, Badros, A, Catchatourian, R, Ketterling, R, Kyle, R A, Kumar, S, Vachon, C M, Rajkumar, S V

“…We examined four clinically assessed cytogenetic subtypes (t(11;14), t(4;14), monosomy 13/del13q and monosomy 17/del17p in 292 black patients with newly…”
Get full text

Phase 1, multicenter, open-label, dose-escalation, combination study (NCT02103335) of pomalidomide (POM), marizomib (MRZ, NPI-0052), and dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma (MM); study NPI-0052-107 preliminary results by Spencer, A, Badros, A, Laubach, J, Harrison, S, Zonder, J, Chauhan, D, Anderson, K, Reich, S, Trikha, M, Richardson, P

Get full text

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications by ZANGARI, M, SAGHAFIFAR, F, SIEGEL, E, BARLOGIE, B, FINK, L, TRICOT, G, ANAISSIE, E, BADROS, A, DESIKAN, R, FASSAS, A, MEHTA, P, MORRIS, C, TOOR, A, WHITFIELD, D

“…Thromboembolism is not uncommon in multiple myeloma (MM) patients on treatment, but its pathogenesis remains poorly understood. We report the results of a…”
Get full text

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study by Greenberg, A J, Philip, S, Paner, A, Velinova, S, Badros, A, Catchatourian, R, Ketterling, R, Kyle, R A, Kumar, S, Vachon, C M, Rajkumar, S V

Get full text

P07: RESULTS FROM THE CC‐220‐MM‐001 DOSE‐EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by Donk, N. W. C. J, Popat, R, Hulin, C, Jagannath, S, Oriol, A, Richardson, P. G, Facon, T, Weisel, K, Larsen, J. T, Minnema, M, Abdallah, A, Badros, A. Z, Knop, S, Stadtmauer, E. A, Chen, M, Nguyen, T. V, Amin, A, Peluso, T, Lonial, S

Get full text